This article was originally published in The Gray Sheet
Executive SummaryShipments of the Venus erbium laser will begin in early July following receipt of 510(k) clearance to market the system for dermatology, cosmetic and plastic surgery, general surgery, gynecology, ear, nose and throat and ophthalmology applications. Laserscope initially will target customers in the skin resurfacing market, the company says. Venus incorporates the SmartScan Plus computer-controlled scanning device and a microprocessor ideal for skin resurfacing, the company claims...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.